Aardvark Therapeutics, Inc. (NasdaqGS: AARD)
Health Care · Pharmaceuticals · US
$4.45
-6.51% today · -71.3% 1Y
Aardvark Therapeutics, Inc. (NasdaqGS: AARD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $104.17M and employs 28 people.
Over the last twelve months the share price has lost 71.3%, trading between 3.35 and 17.94.
Tweenvest scores Aardvark Therapeutics, Inc. across four factors: quality 44/100, value 37/100. Its strongest factor is quality.
AARD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $104.17M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.20
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $17.94
- 52-week low
- $3.35
- Avg volume (3M)
- —
- Shares outstanding
- 21.88M
- Employees
- 28
- Next earnings
- —
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
- ISIN
- US0029421007
- Founded
- 2017
- Listed since
- Feb 13, 2025
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Jushi Holdings Inc.OTCPK: JUSH | $105.41M | $0.53 | -7.39% |
| Cumberland Pharmaceuticals Inc.NasdaqGS: CPIX | $105.33M | $6.95 | -1.21% |
| Nang Kuang Pharmaceutical Co., Ltd.TWSE: 1752 | $105.02M | NT$33.25 | +5.72% |
| Vita Life Sciences LimitedASX: VLS | $104.53M | AU$2.78 | -0.71% |
| Themis Medicare LimitedBSE: 530199 | $103.78M | Rs109.05 | -4.43% |
| PolyPid Ltd.NasdaqCM: PYPD | $102.98M | $5.08 | +0.20% |
| Bafna Pharmaceuticals LimitedNSEI: BAFNAPH | $102.17M | Rs418.00 | +10.36% |
| October Pharma S.A.ECASE: OCPH | $101.60M | EGP221.69 | -1.00% |
Figures last refreshed Oct 11, 2026.